• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Analysis and data insight

Analysis and data insight
Analysis and data insight RSS Feed RSS

Telehealth illustration
COVID-19

Amid pandemic, companies scramble to salvage trials, move virtual

April 14, 2020
By Brian Orelli
In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials.
Read More

‘It’s a humanitarian effort’: Led by Takeda and CSL Behring, a plasma coalition forms to fight COVID-19

April 14, 2020
By Lee Landenberger
A new, worldwide coalition of plasma companies seeking to develop and deliver a hyperimmune immunoglobulin therapy for fighting COVID-19 takes the view that many hands make light work.
Read More
Silhouette with keyhole

Promising pipeline for disease-modifying therapies targeting Parkinson’s disease

April 14, 2020
By Peter Winter
It has been more than 200 years since British doctor James Parkinson first identified the symptoms of a condition that he termed shaking palsy; unfortunately, there is still no cure to the disease that carries his name.
Read More
Telehealth illustration
COVID-19

Amid pandemic, companies scramble to salvage trials, move virtual

April 13, 2020
By Brian Orelli
In order to redirect health care resources and protect patients during the COVID-19 pandemic, many drug companies have paused enrollment in some or all of their ongoing clinical trials. But patients still in the studies need to be followed for safety and efficacy, creating challenges for the industry.
Read More

Week in review for April 6-10, 2020: Biopharmas keep cash rolling in and deals flowing

April 13, 2020
By Peter Winter
A quick look back at top stories.
Read More

Money raised by biopharma: 2020 vs. 2019

April 10, 2020
Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.
Read More

Biopharma money raised: Jan. 1-April 9, 2020

April 10, 2020
Year-to-date money raised in public, private and other financings of biopharma companies.
Read More
Test tube, dropper

Phase I clinical trials: March 2020

April 10, 2020
Therapeutic area data reported by biopharma companies on phase I trials in March 2020, including: Actinium, Allergan, Aptevo, Aravive, Arrowhead, Artugen, Asana, Biocryst, Biomx, Bolt, Cabaletta, CNS, Cohbar, Compugen, Cyclo, Cytodyn, Dare, Debiopharm, Decibel, Discgenics, Dynacure, Enlivex, Eton, Evelo, Faron, Fulcrum, Gemoab, Genetx, Gilead Sciences, GT, Imcheck, Immutep, Inflarx, Inflazome, Inmed, Innate, Kancera, Kiniksa, Lattice, Matinas, Medivir, Mersana, Mina, Moderna, Novartis, Oncolytics, Oncopeptides, Oncternal, Orchard, Pliant, Prevail, Psioxus, Redhill, Seelos, Synlogic, Targovax, Terns, Tolero, Uniqure.
Read More
Biopharma research illustration

Phase II clinical trials: March 2020

April 10, 2020
Therapeutic area data reported by biopharma companies on phase II trials in March 2020, including: Acceleron, Akero, Albireo, Algernon, Allakos, Axsome, Can-Fite, Cellphire, Chugai, Cortexyme, Cytodyn, Delmar, Diffusion, Engage, Genfit, Hansa, Horizon, Ideaya, Immutep, Innovent, Inovio, Irlab, ISA, Leading, Matinas, Mediwound, Moderna, Nantkwest, Neuraly, Obseva, Oncolys, Oncoquest, Opthea, Orchard, Orphomed, Orthotrophix, Ovid, Palvella, Phasebio, Proqr, Qurient, Redhill, Regeneron, Revive, Sanofi, Santen, Seres, Synlogic, Tenax, Theralase, Theranexus, Tracon, Uniqure, Vaccitech, Vivoryon, Xenon, Zealand.
Read More
Hand holding gear, dollar sign
Q1 financings

Private med-tech money towers, public raises fall short, but Q1 solid overall

April 10, 2020
By Karen Carey
During the first quarter of 2020, a total of 153 financings brought $13.2 billion into the med-tech industry, representing a 20% drop from the first quarter of 2019, but still significantly above all of the other quarters since 2017. The number of private financings appears to be climbing in comparison with recent years, and some large notes offerings have placed private raises of public companies on top. In contrast, IPOs and follow-on offerings are way down from previous quarters.
Read More
Previous 1 2 … 225 226 227 228 229 230 231 232 233 … 261 262 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 4, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 4, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • KT-621: a first-in-class STAT6 degrader for Th2-driven diseases

    BioWorld Science
    STAT6 plays a central role in regulating Th2-driven immune responses. Recent studies have identified gain-of-function mutations in the STAT6 gene that are...
  • Woman holding neck

    Merus combo trounces Keytruda in head-and-neck phase II

    BioWorld
    Investor hopes rose sharply for Merus NV’s phase III trials – data should roll out next year – with bispecific antibody petosemtamab after mid-stage results...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe